0
0
LONDON — A large, randomized clinical trial published this month found that commonly used mucoactive (mucus-loosening or -clearing) treatments did not improve breathing for patients with acute respiratory failure in intensive care units (ICUs). Furthermore, in some cases, the treatments were associated with potential clinical harm, prompting clinicians worldwide to critically re-evaluate the routine use of these agents in critically ill patients.
The multicenter study, reported in Medical Xpress on July 1, 2026, evaluated whether mucoactive therapies help mechanically ventilated patients clear stubborn airway secretions and improve overall respiratory outcomes in the high-stakes ICU setting (MARCH Trial Investigators, 2026). The robust results are challenging decades of standard respiratory care protocols.
Key Findings Challenge Standard ICU Protocols
For generations, managing dense lung secretions has been considered foundational to keeping an intubated patient’s airway clear. However, the newly released data from the landmark MARCH trial—which evaluated the enteral mucoregulator carbocisteine and inhaled hypertonic saline—showed no clear clinical benefit from routine mucoactive therapy for patients experiencing acute respiratory failure in intensive care (MARCH Trial Investigators, 2026). Efficacy was measured rigorously by respiratory ease, successful weaning from mechanical ventilation, and related clinical outcomes.
Crucially, rather than simply proving ineffective, some measures within the trial pointed to potential harms or, at best, a total lack of improvement in patient-centered outcomes. Mechanically ventilated patients who routinely received these interventions did not see a reduction in the duration of their mechanical ventilation. Instead, the administration of these agents was linked to a higher treatment burden and secondary complications, casting serious doubt on the long-standing practice of prescribing these drugs automatically to ventilated individuals.
Experts Urge Shift Away from “Blanket” Prescriptions
Medical experts are urging a measured but decisive shift in how intensive care units manage secretions.
“While mucus management is a long-standing component of respiratory care, high-quality evidence for routine mucoactive use in the ICU has been limited until now,” explained Dr. Elizabeth Vance, an independent critical care physician at the London Health Sciences Centre who was not involved in the trial. “For years, clinicians relied on physiological plausibility—the idea that thinning mucus must inherently help a patient on a ventilator. This trial provides the definitive, large-scale data we desperately needed to guide evidence-based practice and protect patients from unnecessary interventions.”
However, specialists emphasize that these findings do not mean mucoactive drugs should be banned from hospitals entirely. “We must differentiate between routine protocolized use and targeted therapies,” cautioned Dr. Vance. “Mucoactive agents may still hold a vital role in selected patients, such as individuals with pre-existing chronic hypersecretive lung diseases like cystic fibrosis or advanced bronchiectasis. What this trial clearly demonstrates is that routine blanket use in all ventilated ICU patients is entirely unsupported by clinical evidence.”
Context: Filling a Massive Gap in Medical Evidence
Mucoactive agents comprise a highly diverse group of pharmaceuticals, including oral expectorants, inhaled mucolytics, and osmotic drugs designed to alter mucus viscosity or accelerate clearability. In standard hospital operations, they are extensively utilized to aid airway clearance in critically ill patients who lack the muscular strength or conscious reflex to cough effectively on their own.
Historically, the medical community’s justification for these drugs stemmed from small-scale trials, laboratory mechanistic studies, or data extrapolated from outpatient settings. A prior clinical point-prevalence survey highlighted that nearly 41.4% of all invasively ventilated adult ICU patients were actively prescribed mucoactives, demonstrating how deeply ingrained the practice had become despite a lack of rigorous, large-scale validation (MARCH Trial Investigators, 2026). The MARCH trial directly addresses this longstanding evidence gap, moving clinical medicine away from historical habits and toward concrete data.
Broad Implications for Public Health and Clinical Care
The trial’s findings carry immediate ripple effects across multiple levels of healthcare delivery:
-
For Clinicians: The data strongly suggests an immediate halt to the routine, protocolized use of mucoactive drugs in all mechanically ventilated ICU patients. Clinicians are advised to transition to a de-escalation model, reserving these agents exclusively for specific, individualized clinical indications where a mechanism of benefit is highly plausible.
-
For Hospitals and Policymakers: These results are expected to rapidly influence ICU care bundles, hospital medication formularies, and institutional pharmacy stewardship programs. By removing ineffective medications from standard ventilation protocols, hospitals can substantially reduce healthcare costs, minimize pharmacy preparation workloads, and lower the risk of iatrogenic (treatment-induced) complications.
-
For Patients and Families: Embracing simpler, evidence-based care bundles directly reduces a patient’s exposure to unnecessary treatments and their associated side effects. Families can take comfort in knowing that a reduction in the number of nebulizers or pills administered often reflects a safer, more refined approach to critical care.
Limitations and Alternative Perspectives
While the impact of the trial is profound, scientists note that certain nuances must be taken into account. The initial reports summarize the broad trial findings but do not replace a granular review of the primary peer-reviewed publication. Clinicians are encouraged to examine the primary manuscript to evaluate specific drug dosing regimens, patient selection criteria, and secondary statistical analyses (MARCH Trial Investigators, 2026).
Furthermore, because mucoactive agents utilize vastly different mechanisms—some break down chemical bonds to thin mucus, while others alter secretion volume or stimulate the cough reflex—it remains possible that distinct sub-types of medications or specific patient phenotypes could still derive an advantage. Subgroup meta-analyses and future targeted trials will be necessary to fully map out these narrow clinical niches. Additionally, as with any single breakthrough trial, replication across diverse international cohorts is highly valuable before a practice change is deemed completely universal.
What This Means for Your Daily Health Decisions
If you or a loved one is currently receiving intensive care and mucus-clearing medications are integrated into the treatment plan, this study serves as a practical talking point. Families are encouraged to ask the attending care team why each specific medication is being utilized and whether it is expected to meaningfully change clinical outcomes for that specific patient.
For the general public managing chronic respiratory conditions outside of the hospital, it is vital to note that this trial does not address outpatient care. If you take mucoactive medications at home for stable chronic obstructive pulmonary disease (COPD), bronchitis, or other non-ventilated ailments, your treatment is guided by entirely separate bodies of medical evidence (Li et al., 2026). You should not alter your daily medication regimen without consulting your primary pulmonologist.
References
- https://medicalxpress.com/news/2026-07-common-mucus-treatments-dont-icu.html
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
